Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
Regeneron is deepening its foothold in Japan’s oncology market, adding over 50 sales reps this summer as it looks to capitalize on the expanded use of Libtayo (cemiplimab) and build on the country’s role as a priority market for future…
To read the full story
Related Article
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Regeneron to Hire 73 Rhinology Sales Reps to Back Dupixent Label Expansion
August 28, 2024
- Regeneron Takes Over Japan Marketing Authorization for Libtayo from Sanofi
June 4, 2024
- Regeneron Set for Commercial Expansion in Japan, Eyes Dupixent Ramp-Up
May 1, 2024
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
BUSINESS
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Servier’s Voranigo Seen as Potential Standard of Care for Glioma: Expert
May 22, 2026
- Ultragenyx’s LC-FAOD Therapy Dojolvi Now Available in Japan
May 22, 2026
- SanBio Debuts Akuugo Stem Cell Therapy for Traumatic Brain Injury
May 22, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…